Cargando…

A Clinical Prediction Model to Predict Heparin Treatment Outcomes and Provide Dosage Recommendations: Development and Validation Study

BACKGROUND: Unfractionated heparin is widely used in the intensive care unit as an anticoagulant. However, weight-based heparin dosing has been shown to be suboptimal and may place patients at unnecessary risk during their intensive care unit stay. OBJECTIVE: In this study, we intended to develop an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dongkai, Gao, Jianwei, Hong, Na, Wang, Hao, Su, Longxiang, Liu, Chun, He, Jie, Jiang, Huizhen, Wang, Qiang, Long, Yun, Zhu, Weiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176336/
https://www.ncbi.nlm.nih.gov/pubmed/34014171
http://dx.doi.org/10.2196/27118
_version_ 1783703240541470720
author Li, Dongkai
Gao, Jianwei
Hong, Na
Wang, Hao
Su, Longxiang
Liu, Chun
He, Jie
Jiang, Huizhen
Wang, Qiang
Long, Yun
Zhu, Weiguo
author_facet Li, Dongkai
Gao, Jianwei
Hong, Na
Wang, Hao
Su, Longxiang
Liu, Chun
He, Jie
Jiang, Huizhen
Wang, Qiang
Long, Yun
Zhu, Weiguo
author_sort Li, Dongkai
collection PubMed
description BACKGROUND: Unfractionated heparin is widely used in the intensive care unit as an anticoagulant. However, weight-based heparin dosing has been shown to be suboptimal and may place patients at unnecessary risk during their intensive care unit stay. OBJECTIVE: In this study, we intended to develop and validate a machine learning–based model to predict heparin treatment outcomes and to provide dosage recommendations to clinicians. METHODS: A shallow neural network model was adopted in a retrospective cohort of patients from the Multiparameter Intelligent Monitoring in Intensive Care III (MIMIC III) database and patients admitted to the Peking Union Medical College Hospital (PUMCH). We modeled the subtherapeutic, normal, and supratherapeutic activated partial thromboplastin time (aPTT) as the outcomes of heparin treatment and used a group of clinical features for modeling. Our model classifies patients into 3 different therapeutic states. We tested the prediction ability of our model and evaluated its performance by using accuracy, the kappa coefficient, precision, recall, and the F1 score. Furthermore, a dosage recommendation module was designed and evaluated for clinical decision support. RESULTS: A total of 3607 patients selected from MIMIC III and 1549 patients admitted to the PUMCH who met our criteria were included in this study. The shallow neural network model showed results of F1 scores 0.887 (MIMIC III) and 0.925 (PUMCH). When compared with the actual dosage prescribed, our model recommended increasing the dosage for 72.2% (MIMIC III, 1240/1718) and 64.7% (PUMCH, 281/434) of the subtherapeutic patients and decreasing the dosage for 80.9% (MIMIC III, 504/623) and 76.7% (PUMCH, 277/361) of the supratherapeutic patients, suggesting that the recommendations can contribute to clinical improvements and that they may effectively reduce the time to optimal dosage in the clinical setting. CONCLUSIONS: The evaluation of our model for predicting heparin treatment outcomes demonstrated that the developed model is potentially applicable for reducing the misdosage of heparin and for providing appropriate decision recommendations to clinicians.
format Online
Article
Text
id pubmed-8176336
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-81763362021-06-22 A Clinical Prediction Model to Predict Heparin Treatment Outcomes and Provide Dosage Recommendations: Development and Validation Study Li, Dongkai Gao, Jianwei Hong, Na Wang, Hao Su, Longxiang Liu, Chun He, Jie Jiang, Huizhen Wang, Qiang Long, Yun Zhu, Weiguo J Med Internet Res Original Paper BACKGROUND: Unfractionated heparin is widely used in the intensive care unit as an anticoagulant. However, weight-based heparin dosing has been shown to be suboptimal and may place patients at unnecessary risk during their intensive care unit stay. OBJECTIVE: In this study, we intended to develop and validate a machine learning–based model to predict heparin treatment outcomes and to provide dosage recommendations to clinicians. METHODS: A shallow neural network model was adopted in a retrospective cohort of patients from the Multiparameter Intelligent Monitoring in Intensive Care III (MIMIC III) database and patients admitted to the Peking Union Medical College Hospital (PUMCH). We modeled the subtherapeutic, normal, and supratherapeutic activated partial thromboplastin time (aPTT) as the outcomes of heparin treatment and used a group of clinical features for modeling. Our model classifies patients into 3 different therapeutic states. We tested the prediction ability of our model and evaluated its performance by using accuracy, the kappa coefficient, precision, recall, and the F1 score. Furthermore, a dosage recommendation module was designed and evaluated for clinical decision support. RESULTS: A total of 3607 patients selected from MIMIC III and 1549 patients admitted to the PUMCH who met our criteria were included in this study. The shallow neural network model showed results of F1 scores 0.887 (MIMIC III) and 0.925 (PUMCH). When compared with the actual dosage prescribed, our model recommended increasing the dosage for 72.2% (MIMIC III, 1240/1718) and 64.7% (PUMCH, 281/434) of the subtherapeutic patients and decreasing the dosage for 80.9% (MIMIC III, 504/623) and 76.7% (PUMCH, 277/361) of the supratherapeutic patients, suggesting that the recommendations can contribute to clinical improvements and that they may effectively reduce the time to optimal dosage in the clinical setting. CONCLUSIONS: The evaluation of our model for predicting heparin treatment outcomes demonstrated that the developed model is potentially applicable for reducing the misdosage of heparin and for providing appropriate decision recommendations to clinicians. JMIR Publications 2021-05-20 /pmc/articles/PMC8176336/ /pubmed/34014171 http://dx.doi.org/10.2196/27118 Text en ©Dongkai Li, Jianwei Gao, Na Hong, Hao Wang, Longxiang Su, Chun Liu, Jie He, Huizhen Jiang, Qiang Wang, Yun Long, Weiguo Zhu. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 20.05.2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Li, Dongkai
Gao, Jianwei
Hong, Na
Wang, Hao
Su, Longxiang
Liu, Chun
He, Jie
Jiang, Huizhen
Wang, Qiang
Long, Yun
Zhu, Weiguo
A Clinical Prediction Model to Predict Heparin Treatment Outcomes and Provide Dosage Recommendations: Development and Validation Study
title A Clinical Prediction Model to Predict Heparin Treatment Outcomes and Provide Dosage Recommendations: Development and Validation Study
title_full A Clinical Prediction Model to Predict Heparin Treatment Outcomes and Provide Dosage Recommendations: Development and Validation Study
title_fullStr A Clinical Prediction Model to Predict Heparin Treatment Outcomes and Provide Dosage Recommendations: Development and Validation Study
title_full_unstemmed A Clinical Prediction Model to Predict Heparin Treatment Outcomes and Provide Dosage Recommendations: Development and Validation Study
title_short A Clinical Prediction Model to Predict Heparin Treatment Outcomes and Provide Dosage Recommendations: Development and Validation Study
title_sort clinical prediction model to predict heparin treatment outcomes and provide dosage recommendations: development and validation study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176336/
https://www.ncbi.nlm.nih.gov/pubmed/34014171
http://dx.doi.org/10.2196/27118
work_keys_str_mv AT lidongkai aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT gaojianwei aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT hongna aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT wanghao aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT sulongxiang aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT liuchun aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT hejie aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT jianghuizhen aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT wangqiang aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT longyun aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT zhuweiguo aclinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT lidongkai clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT gaojianwei clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT hongna clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT wanghao clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT sulongxiang clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT liuchun clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT hejie clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT jianghuizhen clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT wangqiang clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT longyun clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy
AT zhuweiguo clinicalpredictionmodeltopredictheparintreatmentoutcomesandprovidedosagerecommendationsdevelopmentandvalidationstudy